MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...

Our 0.5x FY26E sales multiple reflects a balance between discounting near term volatility, and giving credit for 39% EBITDA margins as scale grows and capital allocation is further optimized though ...